Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anthera Pharmaceuticals has reported positive preliminary results from a second multi-center, randomized, double-blind, placebo-controlled Phase IIb clinical trial of once-daily A-002 for the treatment of cardiovascular disease.
Subscribe to our email newsletter
In this second study, administration of A-002 lowered both secretory phospholipase A2 (sPLA2) and low density lipoprotein cholesterol (LDL-C) levels confirming the positive effects of A-002 treatment seen in the twice-daily phospholipase levels and serological markers of atherosclerosis (PLASMA) study.
The second trial has enrolled approximately 140 patients with stable coronary heart disease in the US. Subjects were randomized to receive one of two different daily doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was reduction in sPLA2 levels. Secondary endpoints included a number of lipid and inflammatory biomarkers.